# A Study of SH009 Injection in Patients With Advanced Solid Tumors.

> **NCT07390838** · PHASE1 · RECRUITING · sponsor: **Nanjing Sanhome Pharmaceutical, Co., Ltd.** · enrollment: 150 (estimated)

## Conditions studied

- Liver Cancer (Locally Advanced or Metastatic)
- Lung Cancer (NSCLC)
- Head and Neck Cancer Squamous Cell Carcinoma
- Breast Cancer (Locally Advanced or Metastatic)
- Esophageal Cancer
- Gastric Cancer (GC)
- Solid Tumor Malignancies

## Interventions

- **DRUG:** SH009

## Key facts

- **NCT ID:** NCT07390838
- **Lead sponsor:** Nanjing Sanhome Pharmaceutical, Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-16
- **Primary completion:** 2026-12-30
- **Final completion:** 2028-12-30
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07390838

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07390838, "A Study of SH009 Injection in Patients With Advanced Solid Tumors.". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT07390838. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*